标题
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy
作者
关键词
DNA damage Response, Synthetic lethality, Small molecule inhibitors
出版物
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 230, Issue -, Pages 114109
出版商
Elsevier BV
发表日期
2022-01-13
DOI
10.1016/j.ejmech.2022.114109
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase I study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer
- (2021) Seung Tae Kim et al. CLINICAL CANCER RESEARCH
- GDC-0575, a CHK1 Inhibitor, Impairs the Development of Colitis and Colitis-Associated Cancer by Inhibiting CCR2+ Macrophage Infiltration in Mice
- (2021) Min Li et al. OncoTargets and Therapy
- Discovery of Novel Apigenin–Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer
- (2021) Huan Long et al. JOURNAL OF MEDICINAL CHEMISTRY
- PARP and PARG inhibitors in cancer treatment
- (2020) Dea Slade GENES & DEVELOPMENT
- Targeting DNA-PK in cancer
- (2020) Giovanna Damia MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy
- (2020) Lukas Gorecki et al. PHARMACOLOGY & THERAPEUTICS
- Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
- (2020) Stephen A. Jannetti et al. Frontiers in Pharmacology
- Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
- (2020) José Yélamos et al. Cancers
- PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
- (2020) Ahrum Min et al. Cancers
- Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma
- (2020) Linsong Tang et al. CANCER LETTERS
- Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer
- (2020) Biagio Ricciuti et al. CLINICAL CANCER RESEARCH
- Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study
- (2020) Erika J Lampert et al. CLINICAL CANCER RESEARCH
- Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models
- (2020) Frank T. Zenke et al. MOLECULAR CANCER THERAPEUTICS
- Biomarker-Guided Development of DNA Repair Inhibitors
- (2020) James M. Cleary et al. MOLECULAR CELL
- Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial
- (2020) Catherine Hanna et al. NEURO-ONCOLOGY
- Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer
- (2020) Yunlong Hu et al. CANCER SCIENCE
- Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models
- (2020) Ulrich Lücking et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-activity relationships of Wee1 inhibitors: A review
- (2020) Xingkai Du et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
- (2020) Timothy A. Yap et al. Cancer Discovery
- PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
- (2020) Maddison Rose et al. Frontiers in Cell and Developmental Biology
- Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010-present)
- (2020) Suwen Hu et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Rucaparib: A Review in Ovarian Cancer
- (2019) Matt Shirley Targeted Oncology
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer
- (2019) Paul Dent EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach
- (2019) Stergios Boussios et al. INVESTIGATIONAL NEW DRUGS
- The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models
- (2019) Antje M. Wengner et al. MOLECULAR CANCER THERAPEUTICS
- Synthetic lethality as an engine for cancer drug target discovery
- (2019) Alan Huang et al. NATURE REVIEWS DRUG DISCOVERY
- AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
- (2019) Jacqueline H. L. Fok et al. Nature Communications
- WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer
- (2019) Andrea Sand et al. CANCER LETTERS
- Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient‐derived osteosarcoma cells and synergizes with cisplatin and talazoparib
- (2019) Christopher L. Heidler et al. INTERNATIONAL JOURNAL OF CANCER
- The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor
- (2019) Frederick W. Goldberg et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors
- (2018) A Italiano et al. ANNALS OF ONCOLOGY
- PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials
- (2018) Dalia Kamel et al. CURRENT DRUG TARGETS
- Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors
- (2018) Anish Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors
- (2018) Bin Yang et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one)
- (2018) Kurt G. Pike et al. JOURNAL OF MEDICINAL CHEMISTRY
- The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells GrownIn Vitroand as Orthotopic Xenografts
- (2018) Cindy R. Timme et al. MOLECULAR CANCER THERAPEUTICS
- The comings and goings of PARP-1 in response to DNA damage
- (2018) John M. Pascal DNA REPAIR
- Niraparib: A Review in Ovarian Cancer
- (2018) Young-A Heo et al. Targeted Oncology
- Talazoparib: First Global Approval
- (2018) Sheridan M. Hoy DRUGS
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- Directing the use of DDR kinase inhibitors in cancer treatment
- (2017) Inger Brandsma et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
- (2017) Ahrum Min et al. MOLECULAR CANCER THERAPEUTICS
- ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
- (2017) Andrew N. Blackford et al. MOLECULAR CELL
- Synthetic lethality screens point the way to new cancer drug targets
- (2017) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Synthetic lethality and cancer
- (2017) Nigel J. O'Neil et al. NATURE REVIEWS GENETICS
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Translational research in radiation-induced DNA damage signaling and repair
- (2017) Jac A. Nickoloff et al. Translational Cancer Research
- Targeting the ATR-CHK1 Axis in Cancer Therapy
- (2017) Stuart Rundle et al. Cancers
- PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
- (2016) Benjamin H. Lok et al. CLINICAL CANCER RESEARCH
- Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
- (2016) S. Percy Ivy et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy
- (2016) Ying-Qing Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting WEE1 Kinase in Cancer
- (2016) Christopher J. Matheson et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Kinase hinge binding scaffolds and their hydrogen bond patterns
- (2015) Li Xing et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Targeting the DNA Damage Response in Cancer
- (2015) Mark J. O’Connor MOLECULAR CELL
- PARP-1 Activation Requires Local Unfolding of an Autoinhibitory Domain
- (2015) Jennine M. Dawicki-McKenna et al. MOLECULAR CELL
- DDR-mediated crosstalk between DNA-damaged cells and their microenvironment
- (2015) Nicolas Malaquin et al. Frontiers in Genetics
- Beyond DNA Repair: DNA-PK Function in Cancer
- (2014) J. F. Goodwin et al. Cancer Discovery
- Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone
- (2014) Mika Aoyagi-Scharber et al. Acta Crystallographica Section F-Structural Biology Communications
- Roles of Chk1 in cell biology and cancer therapy
- (2013) Youwei Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Targeting the DNA damage response in oncology
- (2012) Bristi Basu et al. CURRENT OPINION IN ONCOLOGY
- Unleashing Chk1 in cancer therapy
- (2011) Laura Carrassa et al. CELL CYCLE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started